Eagle Pharmaceuticals Announces Divestiture of Barhemsys

Core Insights - Eagle Pharmaceuticals has divested the marketing authorization for Barhemsys (amisulpride) in the U.S. to LXO Group, Paris, France, as part of its strategy to streamline its acute care business and maximize shareholder value [1][3] Company Overview - Eagle Pharmaceuticals is a fully integrated pharmaceutical company with expertise in research and development, clinical, manufacturing, and commercial operations. The company focuses on developing innovative medicines that improve patients' lives [5] Product Information - Barhemsys is the only FDA-approved treatment for Postoperative Nausea and Vomiting (PONV), launched in the U.S. in November 2020, addressing a significant need in post-surgical care [2] - The treatment can be used alone or in combination with another antiemetic for patients with or without prior prophylaxis [2] Strategic Implications - The divestiture is expected to enhance Eagle's commercial capabilities and create synergies with LXO Group's existing U.S. portfolio, as both companies will utilize the same distribution channel [4] - Cash generated from the divestiture will be allocated to Eagle's ongoing business operations [4]